Newsroom

Tuesday, December 6, 2011
Mira Dx highlights breakthrough publication describing a marker for resistance to Platinum treatment in Ovarian Cancer
Tue, 12/06/2011 A new breakthrough study, published in Oncogene, demonstrates the utility of the KRAS-variant in identifying ovarian cancer patients at highest risk for resistance to platinum chemotherapy.
Read more >

Wednesday, March 23, 2011
Importance of the KRAS-variant in early onset breast cancer shown in research study
New breakthrough study, published in Lancet Oncology, demonstrates association with triple-negative breast cancer
Read more >

Friday, February 25, 2011
Mira Dx Licenses Triple Negative Breast Cancer Risk Variant from Yale University
Mira Dx announced today that it has licensed technology from Yale University ...
Read more >

Thursday, December 9, 2010
Mira Dx Names Martin Verhoef, President and Chief Executive Officer
MiraDx today announced that Martin L. Verhoef has been appointed President and Chief Executive Officer effective immediately.
Read more >

Monday, August 2, 2010
Mira Dx Launches PreOvar Test for Ovarian Cancer Risk
New test leverages microRNA technology from Yale University
Read more >

Thursday, May 13, 2010
Mira Dx receives CLIA Certificate of Compliance from the Centers for Medicare & Medicaid Services

Friday, April 23, 2010
Mira Dx receives State of Connecticut Clinical Laboratory License

Thursday, December 17, 2009
Mira Dx takes occupancy of 4000 sq ft at 300 George Street in New Haven, CT